SCHEDULE 13G: Woodline Partners Discloses 5.2% Passive Stake in Aligos Therapeutics
Beneficial Ownership Report
Woodline Partners LP has filed a Schedule 13G, reporting a 5.2% beneficial ownership stake in Aligos Therapeutics, Inc. as of March 31, 2025.
Summary
- Woodline Partners LP, a Delaware limited partnership and investment adviser to Woodline Master Fund LP, has reported beneficial ownership of 315,383 shares of Common Stock in Aligos Therapeutics, Inc.
- This ownership represents 5.2% of Aligos Therapeutics' outstanding Common Stock.
- The percentage is calculated based on 6,114,311 shares of Common Stock outstanding as of March 6, 2025, as reported in the Company's Annual Report on Form 10-K filed on March 10, 2025.
- The filing is a Schedule 13G, indicating that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment as it does not contain operational or financial performance updates, nor does it indicate any activist intent.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a standard disclosure by an investment adviser, Woodline Partners LP, indicating a significant but passive ownership stake in a biotechnology company, Aligos Therapeutics, Inc. Such filings are routine for institutional investors crossing specific ownership thresholds and typically do not imply strategic or operational involvement.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, confirming a passive investment approach.
Key Dates
| Date | Description |
|---|---|
| 2025-03-06 | Date as of which Aligos Therapeutics' Common Stock outstanding (6,114,311 shares) was reported in their Annual Report on Form 10-K. |
| 2025-03-10 | Date Aligos Therapeutics filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the SEC. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement by Woodline Partners LP. |
| 2025-05-15 | Date the Schedule 13G statement was signed by Woodline Partners LP. |
Keywords
Aligos Therapeutics, Woodline Partners, SEC filing, Schedule 13G, beneficial ownership, investment adviser, common stock, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.